Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc.verified

ICPT

Price:

$19

Market Cap:

$794.69M

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United State...[Read more]

Industry

Biotechnology

IPO Date

2012-10-11

Stock Exchange

NASDAQ

Ticker

ICPT

The Enterprise Value as of June 2024 (TTM) for Intercept Pharmaceuticals, Inc. (ICPT) is 915.81M

According to Intercept Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 915.81M. This represents a change of 15.22% compared to the average of 794.81M of the last 4 quarters.

Intercept Pharmaceuticals, Inc. (ICPT) Historical Enterprise Value (quarterly & annually)

How has ICPT Enterprise Value performed in the past?

The mean historical Enterprise Value of Intercept Pharmaceuticals, Inc. over the last ten years is 2.11B. The current 915.81M Enterprise Value has changed 4.25% with respect to the historical average. Over the past ten years (40 quarters), ICPT's Enterprise Value was at its highest in in the March 2014 quarter at 6.30B. The Enterprise Value was at its lowest in in the June 2023 quarter at 658.73M.

Quarterly (TTM)
Annual

Average

2.11B

Median

1.87B

Minimum

700.53M

Maximum

4.39B

Intercept Pharmaceuticals, Inc. (ICPT) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Intercept Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 1.06%

Maximum Annual Enterprise Value = 4.39B

Minimum Annual Increase = -69.67%

Minimum Annual Enterprise Value = 700.53M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2022700.53M-28.62%
2021981.47M-26.30%
20201.33B-69.67%
20194.39B56.60%
20182.80B99.65%
20171.40B-39.77%
20162.33B-19.89%
20152.91B-3.06%
20143.00B146.59%
20131.22B1.06%

Intercept Pharmaceuticals, Inc. (ICPT) Average Enterprise Value

How has ICPT Enterprise Value performed in the past?

The current Enterprise Value of Intercept Pharmaceuticals, Inc. (ICPT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

1.00B

5-year avg

2.04B

10-year avg

2.11B

Intercept Pharmaceuticals, Inc. (ICPT) Enterprise Value vs. Peers

How is ICPT’s Enterprise Value compared to its peers?

Intercept Pharmaceuticals, Inc.’s Enterprise Value is less than Viking Therapeutics, Inc. (5.39B), greater than Terns Pharmaceuticals, Inc. (467.85M), less than Akero Therapeutics, Inc. (1.05B), less than Reata Pharmaceuticals, Inc. (6.68B), less than Madrigal Pharmaceuticals, Inc. (5.37B), less than TG Therapeutics, Inc. (2.56B), greater than Hepion Pharmaceuticals, Inc. (-6481245.00), less than PTC Therapeutics, Inc. (2.64B), less than Krystal Biotech, Inc. (4.72B), greater than AVROBIO, Inc. (-25444135.00), greater than CohBar, Inc. (-3924938.00), greater than Ocean Biomedical, Inc. (60.22M), greater than Enveric Biosciences, Inc. (-697076.00), greater than Elevation Oncology, Inc. (114.75M), less than Sarepta Therapeutics, Inc. (12.41B), less than Mirati Therapeutics, Inc. (3.91B),

Build a custom stock screener for Intercept Pharmaceuticals, Inc. (ICPT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Intercept Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Intercept Pharmaceuticals, Inc. (ICPT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Intercept Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Intercept Pharmaceuticals, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Intercept Pharmaceuticals, Inc. (ICPT)?

What is the 3-year average Enterprise Value for Intercept Pharmaceuticals, Inc. (ICPT)?

What is the 5-year average Enterprise Value for Intercept Pharmaceuticals, Inc. (ICPT)?

How does the current Enterprise Value for Intercept Pharmaceuticals, Inc. (ICPT) compare to its historical average?